3-Monoiodothyronamine: the rationale for its action as an endogenous adrenergic-blocking neuromodulator.
The investigations reported here were designed to gain insights into the role of 3-monoiodothyronamine (T1AM) in the brain, where the amine was originally identified and characterized. Extensive deiodinase studies indicated that T1AM was derived from the T4 metabolite, reverse triiodothyronine (revT3), while functional studies provided well-confirmed evidence that T1AM has strong adrenergic-blocking effects. Because a state of adrenergic overactivity prevails when triiodothyronine (T3) concentrations become excessive, the possibility that T3's metabolic partner, revT3, might give rise to an antagonist of those T3 actions was thought to be reasonable. All T1AM studies thus far have required use of pharmacological doses. Therefore we considered that choosing a physiological site of action was a priority and focused on the locus coeruleus (LC), the major noradrenergic control center in the brain. Site-directed injections of T1AM into the LC elicited a significant, dose-dependent neuronal firing rate change in a subset of adrenergic neurons with an EC(50)=2.7 microM, a dose well within the physiological range. Further evidence for its physiological actions came from autoradiographic images obtained following intravenous carrier-free (125)I-labeled T1AM injection. These showed that the amine bound with high affinity to the LC and to other selected brain nuclei, each of which is both an LC target and a known T3 binding site. This new evidence points to a physiological role for T1AM as an endogenous adrenergic-blocking neuromodulator in the central noradrenergic system.
Gompf
Heinrich S
HS
Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: heinrich.gompf@gmail.com.
Greenberg
Joel H
JH
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
Aston-Jones
Gary
G
Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA.
Ianculescu
Alexandra G
AG
Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA.
Scanlan
Tom S
TS
Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR, USA.
Dratman
Mary B
MB
Department of Medicine (Endocrinology), University of Pennsylvania, Philadelphia, PA, USA.
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000319:Adrenergic beta-Antagonists / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D008125:Locus Coeruleus / Q000187:drug effects / Q000378:metabolism; D008297:Male; D018377:Neurotransmitter Agents / Q000494:pharmacology / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013970:Thyronines / Q000494:pharmacology / Q000502:physiology; D014284:Triiodothyronine / Q000494:pharmacology / Q000502:physiology*
D000319:Adrenergic beta-Antagonists; D018377:Neurotransmitter Agents; D013970:Thyronines; D014284:Triiodothyronine; C004547:thyronamine